戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 pooled) and 4.4 events per patient-year with insulin lispro.
2 fsitora or glargine U100, both with prandial insulin lispro.
3 , degludec (n=349), both in combination with insulin lispro.
4   The rate of hypoglycemia was 12% less with insulin lispro (6.4 +/- 0.2 vs. 7.2 +/- 0.3 episodes/30
5                                              Insulin lispro, an insulin analog recently developed par
6                                  We compared insulin lispro and regular human insulin in the mealtime
7 NIST), and stressed therapeutic protein DPs, insulin lispro and rituximab.
8      Our studies employed Lys(B28), Pro(B29)-insulin ("lispro") as a model prandial analog that is le
9 nferiority of tirzepatide (pooled cohort) vs insulin lispro, both in addition to insulin glargine, in
10 blood glucose; for instance, the fast-acting insulin lispro contains two point mutations that suppres
11                   No evidence was noted that insulin lispro differs in immunogenicity from RHI in pre
12 was -9.0 kg with tirzepatide and 3.2 kg with insulin lispro (estimated treatment difference, -12.2 kg
13 ledipasvir and sofosbuvir tablets [Harvoni], insulin lispro [Humalog], and insulin aspart [Novolog])
14                               In conclusion, insulin lispro improves postprandial control, reduces hy
15 nsulin glargine, both combined with prandial insulin lispro, in patients with type 2 diabetes.
16       Used as prandial insulin (for example, insulin lispro, insulin aspart, or insulin glulisine) an
17  comparators (glimepiride, insulin glargine, insulin lispro, liraglutide, pioglitazone, or sitaglipti
18                                              Insulin lispro [Lys (B28), Pro (B29) human insulin] is a
19 or 15 mg [n = 236]) or prandial thrice-daily insulin lispro (n = 708).
20                       For patients receiving insulin lispro, no significant changes occurred in antib
21 ) with tirzepatide and 36% (256 of 708) with insulin lispro (odds ratio, 4.2 [95% CI, 3.2-5.5]).
22 en with glargine once daily and rapid-acting insulin lispro or aspart before meals (the basal-bolus g
23  of patients were randomly assigned to begin insulin lispro or continue on RHI.
24 ic pancreas treatment with insulin aspart or insulin lispro or to receive standard care (defined as a
25 t 2 h by 2.0 mmol/l in patients treated with insulin lispro (P < 0.001).
26 tide (pooled cohort) was -2.1% vs -1.1% with insulin lispro, resulting in mean HbA1c levels of 6.7% v
27 esence of insulin-specific antibodies (ISA), insulin lispro-specific antibodies (LSA), and cross-reac
28 umber of hypoglycemic episodes was less with insulin lispro than with regular human insulin therapy d
29 serum glucose was significantly lower during insulin lispro therapy.
30  trials, we contrasted the immunogenicity of insulin lispro versus regular human insulin (RHI) in pat
31                                              Insulin lispro was injected immediately before the meal,
32                    Here we replace ProB29 of insulin lispro with 4R-fluoroproline, 4S-fluoroproline,